MarketCap
Facebook
X
Telegram
Seagen Operating Cycle | SGEN
Annual Operating Cycle Seagen
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 362 | 268 | 216 | 654 | 298 | 611 | 787 | 605 | 590 | 510 | 1.1 K | 1.25 K | 32.7 | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.25 K | 32.7 | 561 |
Quarterly Operating Cycle Seagen
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 367 | 325 | 457 | - | 198 | 155 | 333 | - | 273 | 265 | 278 | 49.3 | 163 | 326 | 422 | 74.3 | 825 | 98.6 | 89.3 | 76.5 | 78.8 | 78.4 | 75 | 59.7 | 57.2 | 71.5 | 61.3 | 53.7 | 53.1 | 59.2 | 47.1 | 51.7 | 57.5 | 62.6 | 51.2 | 48.2 | 47.2 | 52.4 | 46 | 39.9 | 37.9 | 36.6 | 50.1 | 47.8 | 61.2 | 62.5 | 83.6 | 103 | 243 | 384 | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 825 | 36.6 | 147 |
Operating Cycle of other stocks in the Biotechnology industry
| Issuer | Operating Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Sesen Bio
SESN
|
391 | - | 7.29 % | $ 127 M |  USA |
 |
Windtree Therapeutics
WINT
|
164 | - | - | $ 26.8 M | USA |
 |
SQZ Biotechnologies Company
SQZ
|
25.5 | - | 57.95 % | $ 12.8 M | USA |
 |
MEI Pharma
MEIP
|
392 | - | 10.43 % | $ 20.5 M | USA |
 |
Palatin Technologies
PTN
|
6.22 | - | - | $ 13 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
Brickell Biotech
BBI
|
26 | - | -5.38 % | $ 6.06 M | USA |
 |
Generation Bio Co.
GBIO
|
47.6 | - | - | $ 344 M | USA |
 |
Clearside Biomedical
CLSD
|
107 | - | - | $ 25.3 M | USA |
 |
Merus N.V.
MRUS
|
18.6 | - | - | $ 5.78 B |  Niderland |
 |
AbbVie
ABBV
|
350 | $ 294.72 | 0.32 % | $ 521 B | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
33.4 | $ 4.63 | 21.05 % | $ 20 M |  Israel |
 |
Axon Enterprise
AXON
|
98.8 | $ 316.97 | 4.77 % | $ 24.7 B | USA |
 |
Bristol-Myers Squibb Company
BMY
|
153 | $ 62.89 | 0.18 % | $ 128 B | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
19.1 K | - | -15.15 % | $ 60.3 M |  Britain |
 |
Dynavax Technologies Corporation
DVAX
|
512 | - | - | $ 2.02 B | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
86.7 | $ 159.75 | 5.35 % | $ 20.9 B | USA |
 |
Amgen
AMGN
|
282 | $ 467.97 | 0.59 % | $ 252 B | USA |
 |
Orgenesis
ORGS
|
25.8 | - | -33.86 % | $ 61.2 M | USA |
 |
Jazz Pharmaceuticals plc
JAZZ
|
66.2 | $ 248.31 | 1.17 % | $ 15.1 B |  Irlanda |
 |
Johnson & Johnson
JNJ
|
223 | $ 280.31 | -0.17 % | $ 675 B | USA |
 |
Kala Pharmaceuticals
KALA
|
729 | $ 0.17 | 0.64 % | $ 1.39 M | USA |
 |
Sage Therapeutics
SAGE
|
408 | - | - | $ 527 M | USA |
 |
Lineage Cell Therapeutics
LCTX
|
19.2 | $ 1.13 | 8.17 % | $ 260 M | USA |
 |
Paratek Pharmaceuticals
PRTK
|
337 | - | - | $ 121 M | USA |
 |
Eli Lilly and Company
LLY
|
433 | $ 1 437.4 | 0.36 % | $ 1.29 T | USA |
 |
Compugen Ltd.
CGEN
|
400 | $ 2.09 | -0.24 % | $ 195 M | Israel |
 |
Crinetics Pharmaceuticals
CRNX
|
554 | $ 84.95 | 0.13 % | $ 7.99 B | USA |